Anupam Rasayan India Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pshgqbtr2f95od8baw1cbchz.pdf

Key Takeaways


Demand & Volume Recovery

Thakkar: "Our customers have been saying that CY'25 looks far better than CY'24 for sure. For sure. And CY'24 looks better than CY'23, also is a statement I can say."

Working Capital: The Core Problem

Thakkar: "Slow moving in a sense is just that what I had expected them to move, they have not moved at the speed that we had expected. But is there any risk on those inventories? The answer is no. We do not see any."

Revenue Model & Margin Mechanics

Thakkar: "For me, the key important number is EBITDA rather than my revenue in terms of a contract. Volume is assured, margins are assured."

Order Book & New Product Pipeline


Portfolio Shift: Pharma, Polymers & Fluorination


Balance Sheet & Capex


Guidance & Commitments

CommitmentSpecificsTimeline
Working capital correction"Decent correction" this year; target 180–200 daysFY'26
Revenue growthFY'25 will be a year of growth, but first two quarters tepidFY'25 (Q3/Q4 weighted)
Stand-alone marginsAround 26%+Ongoing
Pharma revenue shareReach ~15% of totalNot specified
Fluorination shareGrow by 5–10 percentage points from ~20%Not specified
Polymer growthDouble-digit growthNext fiscal year
Tanfac HF capacityDouble current capacityNext year
New product launches6–8-plus additional productsNext year
Peak revenue potential~₹3,000 crores (including current capex plan)When LOIs fully ramp
CapexBalance ₹180 crores + maintenance; no external financing neededFY'25
Debt reductionPref/warrant proceeds to repay long-term debtNext 12–18 months

Key Metrics

MetricQ4 FY24
Operating revenue₹401 cr, down 16% YoY from ₹480 cr
EBITDA (incl. other income)₹105 cr, down 26% YoY from ₹142 cr
EBITDA margin25% on a consolidated basis, vs 27% in FY23
Profit After Tax₹40 cr, degrowth of 44% YoY from ₹73 cr
FY24 operating revenue₹1,475 cr, down 8.0% YoY from ₹1,602 cr
FY24 EBITDA margin27%, equivalent to last year
FY24 Profit After Tax₹167 cr, down 23% YoY from ₹217 cr
New products added in Q46, summing to 17 new products in FY24
New customers added in Q42, totalling 4 new customers in FY24
Revenue from top 10 customers77% of total revenue, across 25 products
Segment mix: Agro / Personal Care / Pharma / Other Specialty65% / 17% / 9% / 9% for FY24
Fluorination share of revenue~20% in FY24, expected to grow by at least 5 to 10 percentage points
LOI order book~₹9,000 cr, implying ~₹1,300–₹1,400 cr annual revenue over ~6 years
Revenue from six-month pricing contracts~60% of revenue, up from 15–20% at IPO
Stand-alone inventories~₹990 cr, raw material ~30%, WIP and finished goods the balance
Capex incurred as of 31 Mar 2024₹482 cr out of the ₹670 cr plan; ₹180 cr balance capex to execute
Long-term debt repaid from fund-raise₹249 cr during the quarter
Stand-alone margin guidance~26%+